The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Stroke "EGRABIS1"


Phase 2 Results N/A

Summary of Purpose

This randomized controlled trial investigates the effect of a single dose of glucagon-like peptide-1 (GLP-1) receptor agonist in the subacute phase of stroke in humans. The primary endpoint is the mean flow velocity in the middle cerebral arteries measured by transcranial doppler and cortical oxygination measured by near infrared spectroscopy (NIRS). The secondary endpoints are changes in endothelial/inflammatory...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 21 March 2018.

1 Aug 2016 5 Jul 2016 1 Aug 2018 1 Oct 2018 1 Mar 2018 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics




Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Pharmacodynamics Study
  • Intervention: Parallel Assignment